Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent

doi:10.2174/1871520616666161206143251

Residential College	false
Status	已發表Published
	Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent
	Viradiya, Denish; Mirza, Sheefa; Shaikh, Faraz; Kakadiya, Rajesh; Rathod, Anand; Jain, Nayan; Rawal, Rakesh; Shah, Anamik
	2017
Source Publication	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
ISSN	1871-5206
Volume	17 Issue:7 Pages:1003-1013
Abstract	Aims: A series of 1,4-dihydropyridine based compounds bearing benzylpyridinium moiety have been designed and evaluated for in vitro anticancer activity against glioblastoma U87MG, lung cancer A549 and colorectal adenocarcinoma Caco-2 cell lines using the MTT assay.
Keyword	Anticancer Activity Antipoliferative Activity Benzylpyridinium Salt 1,4-dihydropyridine Mtt Assay
DOI	10.2174/1871520616666161206143251
URL	View the original
Indexed By	SCIE
Language	英語English
WOS Research Area	Oncology ; Pharmacology & Pharmacy
WOS Subject	Oncology ; Chemistry, Medicinal
WOS ID	WOS:000403944300014
Publisher	BENTHAM SCIENCE PUBL LTD
The Source to Article	WOS
Scopus ID	2-s2.0-85025133117
Fulltext Access	View Full-Text via DOI View Full-Text via Web of Science
Citation statistics
Document Type	Journal article
Collection	University of Macau
Recommended Citation GB/T 7714	Viradiya, Denish,Mirza, Sheefa,Shaikh, Faraz,et al. Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent[J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17(7), 1003-1013.
APA	Viradiya, Denish., Mirza, Sheefa., Shaikh, Faraz., Kakadiya, Rajesh., Rathod, Anand., Jain, Nayan., Rawal, Rakesh., & Shah, Anamik (2017). Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 17(7), 1003-1013.
MLA	Viradiya, Denish,et al."Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent".ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 17.7(2017):1003-1013.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh